Alphamab Oncology - B (ALPHAMAB-B, 9966.HK) is listed on HKEX. The latest available quote update was captured at 2026-03-26 10:40:17.0.
Quote Snapshot
- Last Price: 7.740 HKD
- Day Change: -0.340 (-4.21%)
- Open: 8.080 HKD
- High: 8.170 HKD
- Low: 7.640 HKD
- Previous Close: 8.080 HKD
- Volume: 1.62 M
- Market Cap: 7.49 B
- P/E Ratio: 42.27
- Dividend Yield: N/A
- Board Lot: 1,000
- ISIN: KYG0330A1013
- Industry: Healthcare - Pharmaceuticals & Biotechnology
Company Overview
Alphamab Oncology is an investment holding company principally engaged in research and development, manufacturing and commercialisation of biologics of oncology. The Company’s in-house pipeline consists of antibody-drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s product pipeline includes KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), JSKN016(HER3/TROP2 bispecific antibody ADC), JSKN033(subcutaneous co-formulation of JSKN003 and KN035), used for indications such as 1L sq NSCLC, 1L HER2+ BC, 1L biliary track cancer, advanced solid tumors, HER2-expressing solid tumors and others.
Risk & Return Metrics
Based on 490 trading days of close price data (daily returns, annualized using 252 trading days).
| Metric | Daily | Annualized |
|---|---|---|
| Expected Return | 0.2838% | 104.24% |
| Risk (Std Dev) | 5.7940% | 91.98% |
| Metric | Value |
|---|---|
| First Price (HKD) | 4.580 |
| Last Price (HKD) | 8.080 |
| Total Return | 76.42% |